Nine months after filing their TROP2-directed antibody-drug conjugate Dato-DXd for a lung cancer indication with the FDA, Daiichi Sankyo and AstraZeneca have pulled the submission.
A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dat
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
